- One New Publication Announcement (posted 23–Oct–2020)
- One New Notice of Intent to Revise (posted 23–Oct–2020)
- One New General Notice (posted 12–Oct–2020)
- Three New Reference Changes (posted 02–Oct–2020)
- Three New Revision Bulletins (posted 25–Sep–2020)
- Two New Interim Revision Announcements (posted 25–Sep–2020)
- One New Notice of Intent to Revise (posted 25–Sep–2020)
- One New General Chapter Prospectus (posted 25–Sep–2020)
- Cumulative List Updated (posted 25–Sep–2020)
- One New Revision Bulletin (posted 21–Sep–2020)
- One New Revision Bulletin (posted 15–Sep–2020)
USP–NF is a combination of two compendia, the United States Pharmacopeia (USP) and the National Formulary (NF). Monographs for drug substances, dosage forms, and compounded preparations are featured in the USP. Monographs for dietary supplements and ingredients appear in a separate section of the USP. Excipient monographs are in the NF.
A monograph includes the name of the ingredient or preparation; the definition; packaging, storage, and labeling requirements; and the specification. The specification consists of a series of tests, procedures for the tests, and acceptance criteria. These tests and procedures require the use of official USP Reference Standards. Medicinal ingredients and products will have the stipulated strength, quality, and purity if they conform to the requirements of the monograph and relevant general chapters.
Tests and procedures referred to in multiple monographs are described in detail in the USP–NF general chapters.
The General Notices provide definitions for terms used in the monographs, as well as information that is necessary to interpret the monograph requirements.
The U.S. Federal Food, Drug, and Cosmetics Act designates the USP–NF as official compendia for drugs marketed in the United States. A drug product in the U.S. market must conform to the standards in USP–NF to avoid possible charges of adulteration and misbranding. Learn more.
Standards Established through a Public Process
USP creates and continuously revises USP–NF standards through a unique public–private collaborative process, which involves pharmaceutical scientists in industry, academia, and government as well as other interested parties from anywhere in the world.